Tim Bagguley
Data Analyst

Profile

Biography

Tim is a member of the Epidemiology and Cancer Statistics Group and works on the Haematological Malignancy Research Network, a specialist population-based registry. In this role, he maps patient pathways from diagnosis, combining treatment, clinical and laboratory data along with routine datasets, such as Hospital Episode Statistics. Tim produces routine reports and statistics as well as conducting more complex statistical modelling of epidemiological data, including time to event analysis. Tim has previously provided analytical support to the European Myelodysplastic Syndromes Registry, applying survival models with time-varying covariates.

Alongside his day-to-day role, Tim is also studying for a PhD, focusing on analysing patient-reported quality of life data and, in particular, the methodology associated with making comparisons with normative populations.

Qualifications

  • BA Economics, University of Cambridge
  • MSc Economics, University of Nottingham

Research

Overview

  • Statistical analysis of population-based data relating to haematological malignancies
  • Analysis of patient-reported quality of life data

Projects

Research group(s)

Epidemiology & Cancer Statistics Group

Publications

Full publications list

Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study
Howell, D., Smith, A., Appleton, S., Bagguley, T., Macleod, U., Cook, G., Patmore, R., Roman, E.
British Journal of Haematology; 2017

  

Conference abstracts

Comparison of 1690 mds patients from the european leukemianet registry and reference populations - evidence for a significant impairment in QOL
Stauder, R., Yu, G., Bagguley, T., Fenaux, P., Symeonidis, A., Sanz, G., Cermak, J., Mittelman, M., Hellstrom-Lindberg, E., Langemeijer, S., Holm, M.S., Madry, K., Malcovati, L., Tatic, A., Germing, U., Savic, A., van Marrewijk, C., Guerci-Bresler, A., Luno, E., Droste, J., Koinig, K., Smith, A., Bowen, D., de Witte, T.
Haematologica; Jun 2016; 101, 16–17.

 

Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World
Smith, A.G., Bagguley, T., Roman, E., Rawstron, A.C., Bailey, J.R., Howell, D., Ashcroft, J., Cathy, B., Cook, G., Patmore, R.
Blood; Dec 2016; 128, 3546–3546.

 

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry
Hoeks, M., Langemeijer, S., Swart, L.D., Bagguley, T., Marrewijk, C. Van, Bowen, D., Cermak, J., Hellstrom-Lindberg, E., Tatic, A., Symeonidis, A., Kraaij, M.G.J.V., Panagiotidis, P., Garelius, H., Culligan, D.J., Krejci, M., Droste, J., Smith, A., Swinkels, D.W., Witte, T. De,
Blood; Dec 2016; 128, 4327–4327.

 

Impact of MDS on health-related quality of life: a comparison of IPSS low-and int-1 risk MDS patients from the European Leukemianet MDS (EUMDS) registry and european reference populations
Stauder, R., Bagguley, T., Smith, A., Fenaux, P., Symeonidis, A., Cermak, J., Sanz, G., Hellstrom-Lindberg, E., Mittelman, M., Malcovati, L.
Haematologica; 2015; 100, 68–69.

 

Chronic lymphocytic leukaemia treatment and outcome in the UK’s population-based haematological malignancy research network
Patmore, R., Smith, A.G., Bagguley, T.C., Howell, D.A., Bailey, J., Burton, C.H., Roman, E.
Hematological Oncology; Jun 2015; 33, 195

 

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry
De Swart, L., Reiniers, C., Bagguley, T., Bowen, D., Cermak, J., Hellstrom-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G., Panagiotidis, P., Garelius, H., Culligan, D., Krejci, M., van Marrewijk, C., Droste, J., Smith, A., Swinkels, D.W., de Witte, T.
Blood; Dec 2015; 126.

 

Transfusions and presence of ringsideroblasts influence hepcidin and ntbi levels in patients with lower-risk myelodysplastic syndromes (MDS) - a report from the European Leukemianet MDS Registry
De Swart, L., Reiniers, C., Bagguley, T., Van Marrewijk, C., Bowen, D., Cermak, J., Hellström-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G., Panagiotidis, P., Garelius, H., Culligan, D., Krejci, M., Droste, J., Smith, A., Swinkels, D., de Witte, T.
Leukemia Research; Apr 2015; 39, Supplement 1, S106–S107

 

Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry
Swart, L.D., Reiniers, C., Bagguley, T., Marrewijk, C. Van, Bowen, D., Cermak, J., Hellström-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G.A., Smith, A., Witte, T. De, 2014
Blood; Dec 2014; 124, 3267–3267.

 

Skeletal-Related Events in Myeloma: A Population-Based Study
Ashcroft, J., Bagguley, T., Smith, A., Wang, H.-I., Howell, D., Sayala, H.A., Cook, G., Jack, A., Patmore, R., Roman, E.
Blood; Nov 2013; 122, 3158–3158.

 

Incidence, clinical management and outcome of peripheral T-cell lymphoma: a population-based study in the UK
Smith, A.G., Bagguley, T., Painter, D., Roman, E., Johnson, R., Jack, A., Patmore, R.
Haematologica; Jun 2012; 97, 652.

Contact details

Tim Bagguley
Data Analyst

Tel: 01904 32(1846)

@HMRN_UK